Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | MGMT | P16455 | 2/20 | 0.43 |
| ▸ | HRAS | P01112 | 1/20 | 0.42 |
| ▸ | GJB2 | P29033 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5828864 | 1.00 | SLC6A2 (0.51) | SLC6A2LGALS8MAOBPDE4DMGMT | |
| SCHEMBL7195901 | 0.87 | SLC6A2 (0.51) | SLC6A2LGALS8PDE4DHRASGJB2 | |
| SCHEMBL7596317 | 0.87 | SLC6A2 (0.51) | SLC6A2LGALS8PDE4DHRASGJB2 | |
| SCHEMBL7596323 | 0.87 | SLC6A2 (0.51) | SLC6A2LGALS8PDE4DHRASGJB2 | |
| SCHEMBL16149142 | 0.87 | SLC6A2 (0.47) | SLC6A2LGALS8GJB2 | |
| SCHEMBL7069950 | 0.85 | LGALS8 (0.57) | SLC6A2LGALS8HRAS | |
| SCHEMBL23758907 | 0.83 | SLC6A2 (0.55) | SLC6A2LGALS8PDE4DGJB2 | |
| SCHEMBL18733413 | 0.83 | SLC6A2 (0.58) | SLC6A2LGALS8PDE4D | |
| SCHEMBL20671069 | 0.83 | SLC6A2 (0.55) | SLC6A2LGALS8PDE4DGJB2 | |
| SCHEMBL6553513 | 0.83 | SLC6A2 (0.55) | SLC6A2LGALS8PDE4DGJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962791-B2 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | WASHINGTON UNIVERSITY (US) | 2005-11-08 | — | — | US | claimed |
| EP-0730601-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2004-07-14 | — | — | EP | claimed |
| US-20030224468-A1 | By interacting with periplasmic molecular chaperones the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished | HULTGREN SCOTT (US) | 2003-12-04 | — | — | US | claimed |
| US-20030198992-A1 | By interacting with periplasmic molecular chaperones so the assemlbly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished; used in drug design | HULTGREN SCOTT (US) | 2003-10-23 | — | — | US | claimed |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-10-10 | — | — | US | claimed |
| US-6420127-B1 | PREVENTION OF MICROORGANISMAL INFECTIONS; OBTAIN MEMBRANES, INCUBATE WITH MODULATORS, MONITOR MICROORGANISMAL INFECTIONS | WASHINGTON UNIVERSITY | 2002-07-16 | — | — | US | claimed |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-04-18 | — | — | US | claimed |
| US-20020034774-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-03-21 | — | — | US | claimed |
| US-7025971-B2 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | WASHINGTON UNIVERSITY (US) | 2006-04-11 | — | — | US | disclosed |
| US-6962791-B2 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | WASHINGTON UNIVERSITY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6872542-B1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | SIGA PHARMACEUTICALS, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-0730601-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030224468-A1 | By interacting with periplasmic molecular chaperones the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished | HULTGREN SCOTT (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030198992-A1 | By interacting with periplasmic molecular chaperones so the assemlbly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished; used in drug design | HULTGREN SCOTT (US) | 2003-10-23 | — | — | US | disclosed |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-10-10 | — | — | US | disclosed |
| US-6420127-B1 | PREVENTION OF MICROORGANISMAL INFECTIONS; OBTAIN MEMBRANES, INCUBATE WITH MODULATORS, MONITOR MICROORGANISMAL INFECTIONS | WASHINGTON UNIVERSITY | 2002-07-16 | — | — | US | disclosed |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-04-18 | — | — | US | disclosed |
| US-20020034774-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-03-21 | — | — | US | disclosed |
| US-6153396-A | DRUG SCREENING BY ADDING COMPOUND TO MIXTURE OF CHAPERONE AND PILUS SUBUNIT AND DETERMINING THE CHANGE IN BINDING; BACTERICIDES FOR URINARY TRACT INFECTIONS | SIGA PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| US-6001823-A | NOVEL PYRANOSIDES WHICH ARE BELIEVED TO BE CAPABLE OF INTERACTING WITH PERIPLASMIC MOLECULAR CHAPERONES | WASHINGTON UNIVERSITY | 1999-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020034774-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | SLC6A2 3235/4885LGALS8 3210/4885MAOB 2625/4885 |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | SLC6A2 3235/4885LGALS8 3210/4885MAOB 2625/4885 |
| US-20030224468-A1 | By interacting with periplasmic molecular chaperones the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished | HSP90B1, HSPBP1, HSPB1 | SLC6A2 3583/4885LGALS8 2815/4885MAOB 3285/4885 |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | SLC6A2 3235/4885LGALS8 3210/4885MAOB 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.